| NCT ID | NCT06702566 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Condition | Immune-related Adverse Event |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-07-04 |
| Primary Completion | 2026-07-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2024-07-04 with a primary completion date of 2026-07-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
Eligibility Criteria
Inclusion Criteria: Only patient who meet all the following conditions can be selected for this trial: 1. Patients voluntarily sign informed consent; 2. The age was 18-75 years old, and the gender was not limited; 3. Patients with definitive diagnosis of malignant solid tumor or acute leukemia; 4. Patients enrolled in will be treated with immunotherapy (including immuno- monotherapy，or immuno- plus targeted therapy, or immuno- plus chemotherapy), or targeted therapy (including targeted monotherapy, or targeted plus chemotherapy), or chemotherapy. 5. The Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 or 2 for physical fitness; 6. Sufficient bone marrow reserve at screening, defined as: * Neutrophil absolute value (ANC) \> 1.5 × 10\^9/L； * Lymphocyte absolute value (ALC) ≥ 0.3 × 10\^9/L； * Platelet (PLT) ≥ 100 × 10\^9/L； * Hemoglobin (HGB) ≥ 100g / L; 7. The screening has appropriate organ function and meets the following criteria: * Aspartate aminotransferase (AST) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN); * Alanine aminotransferase (ALT) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN); * Total serum bilirubin ≤ 1.5 times ULN (due to tumor infiltration ≤ 3 times ULN); * Serum creatinine (SCR) ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60ml / min; * Have the lowest level of lung reserve, defined as ≤ grade 1 dyspnea and oxygen saturation \> 91% in non oxygen breathing state; * International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial prothrombin time (APTT) ≤ 1.5 times ULN; 8. The urine pregnancy test of women of childbearing age is negative. Any male and female patient with fertility must agree to use effective contraceptive methods during the whole study and at least 1 year after the study treatment. Exclusion Criteria: Patient who meet any of the following conditions well excluded in this trial: 1. Active systemic autoimmune disease is known before screening and is under treatment; 2. Those who stopped systemic hormone therapy for less than 2 weeks before enrollment； 3. Those who have received organ / tissue transplantation before screening; 4. Those who meet any of the following conditions during screening: * positive for hepatitis B surface antigen (HBsAg) and / or hepatitis B e antigen (HBeAg); * hepatitis B e antibody (HBE AB) and / or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit; * positive for hepatitis C antibody (HCV AB); * positive anti Treponema pallidum antibody (TP AB); * HIV antibody test positive; * the copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit; 5. The heart meets any of the following conditions during screening: * left ventricular ejection fraction (LVEF) ≤ 50% (echo); * New York Heart Association (NYHA) class III or IV congestive heart failure; * hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension that has not been controlled by standard treatment; * have had myocardial infarction or cardiac surgery within 12 months before cell transfusion; * clinically significant valvular disease. 6. There are clinical emergencies (such as intestinal obstruction or vascular compression) requiring urgent treatment due to tumor body obstruction or compression during screening; 7. Patients with active bleeding during screening; 8. Patients with deep venous thrombosis or pulmonary embolism within 6 months before screening; 9. Those who received live vaccine within 6 weeks before screening; 10. Patients with active infection and need treatment during screening; 11. Poor compliance.
Contact & Investigator
Xiubao Ren, M.D, Ph.D
PRINCIPAL INVESTIGATOR
ianjin Medical University Cancer Institute and Hospital
Frequently Asked Questions
Who can join the NCT06702566 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Immune-related Adverse Event. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06702566 currently recruiting?
Yes, NCT06702566 is actively recruiting participants. Contact the research team at liuliang@tjmuch.com for enrollment information.
Where is the NCT06702566 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06702566 clinical trial?
NCT06702566 is sponsored by Tianjin Medical University Cancer Institute and Hospital. The principal investigator is Xiubao Ren, M.D, Ph.D at ianjin Medical University Cancer Institute and Hospital. The trial plans to enroll 1,500 participants.